This study is testing new ways to treat advanced breast cancer that is hormone receptor-positive (HR+) and HER2-negative. It compares different combinations of medicines: gedatolisib, palbociclib, fulvestrant, ribociclib, and letrozole. The goal is to see which combinations are most effective and safe as a first treatment. You may be eligible if you are an adult male or female with this type of breast cancer, whether it's metastatic (spread) or locally advanced. The main way we'll know if the treatment is successful is by measuring how long people live without their cancer getting worse (Progression Free Survival). The study is currently recruiting a total of 1180 participants.

Study design

This is a Phase 3, open-label, randomized study. Participants will be assigned to one of four treatment groups to compare different drug combinations.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed from the date of randomization until death or for approximately 48 months to measure how long they live without their cancer getting worse.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.